Business Wire

ThreatConnect Releases Risk Quantifier™ 6.0 — Driving Continued Innovation in Cyber Risk Quantification

Share

ThreatConnect Inc.®, the leader in reducing complexity and enabling better decision making in cybersecurity, today released ThreatConnect Risk Quantifier™ 6.0 (RQ 6.0), continuing its innovation in the emerging field of cyber risk quantification.

ThreatConnect Risk Quantifier™ (RQ) enables companies to see the financial risks they face from cyber attacks and also prioritize investments that provide the best ROI. RQ’s calculations are informed by your internal environment, threat intelligence, vulnerability management, operations and response data found within ThreatConnect and other integrations. RQ is distinctly different from other approaches offered in the market as it focuses on automation and data integration, and delivers value in days and weeks as opposed to months and years.

With RQ 6.0 organizations that are looking at financial cyber risk quantification will have the option of leveraging full FAIR scenario’s, using semi-automated FAIR scenario’s, and full automation in one platform.

FAIR is an internationally known standard that has helped companies with awareness and understanding of cyber risk quantification. Organizations implementing FAIR in their CRQ programs have struggled with subjectivity, speed, and actionability, which is why RQ 6.0 is introducing semi-automated FAIR scenario’s that automate a large portion of FAIR in order to reduce complexity and increase time to value for customers.

Semi-Automated FAIR scenarios tackle one of the most challenging aspects of cyber risk quantification - calculating Loss Event Frequency and it’s piece parts. RQ combines data from inside the organization with its own models to evaluate attacker capability against defender strength. Applying this automated calculation to FAIR provides actionable, data-driven results within the FAIR framework and helps organizations transform their manual processes into the scalable, defensible needed to manage the complex risks they face.

“We’ve heard from customers, partners and the broader industry that solutions are needed to address the challenges in adopting and benefiting from CRQ programs,” said ThreatConnect Vice President of Cyber Risk Strategy Gerald Caponera. “Now, through the automation of part of FAIR, organizations can quickly adopt and advance their CRQ programs using their own data combined with ThreatConnect’s analytical capabilities.”

Using a risk-led approach to cybersecurity makes prioritization easy for security teams, enabling them to filter out noise and focus on what matters most. With CRQ, TIP and SOAR capabilities combined, ThreatConnect unifies the actions of the security team around the most critical risks, supports their response with streamlined and automated workflows and strengthens the entire security ecosystem through powerful technology integrations.

Additional details of the release are further outlined in a new blog and video available on the ThreatConnect web site. For more information – click here.

About ThreatConnect

ThreatConnect, Inc. provides cybersecurity software that reduces complexity for everyone, makes decision making easy by turning intelligence into action, and integrates processes and technologies to continually strengthen defenses and drive down risk. Designed by analysts but built for the entire team (security leadership, risk, security operations, threat intelligence, and incident response), ThreatConnect’s decision and operational support platform is the only solution available today with cyber risk quantification, intelligence, automation, analytics, and workflows in one. To learn more about our Cyber Risk Quantification, Threat Intelligence Platform (TIP) or Security Orchestration, Automation, and Response (SOAR) solutions, visit www.ThreatConnect.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Levick U.S.
Maria Stagliano
Phone: +1 202.973-5341
ThreatConnect@levick.com

Lewis U.K.
Jessica Collings
Phone: +44 207.802.2626 | Fax: +44 207.802.2627
hellolondon@teamlewis.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye